role of omega-3 fatty acids in preventing metabolic disturbances in patients on olanzapine plus either sodium valproate or lithium a randomized double-blind placebo-controlled trialω- 3脂肪酸的作用在防止代谢紊乱的病人在奥氮平+丙戊酸钠钠或锂随机双盲安慰剂对照试验.pdfVIP

Faghihi et al. DARU Journal of Pharmaceutical Sciences 2012, 20:43 /content/20/1/43 RESEARCH ARTICLE Open Access Role of Omega-3 fatty acids in preventing metabolic disturbances in patients on olanzapine plus either sodium valproate or lithium: a randomized double-blind placebo-controlled trial 1 2 3,4 4 3,4 Toktam Faghihi , Adel Jahed , Javad Mahmoudi-Gharaei , Vandad Sharifi , Shahin Akhondzadeh and Padideh Ghaeli1,4* Abstract Background: Metabolic and cardiovascular side effects have been noted with the use of second generation antipsychotics (SGAs) and mood stabilizers. Since Omega-3 fatty acids have been known to prevent some cardiovascular risks, this preliminary study was designed to evaluate the cardiovascular benefits of omega-3 when added to the combinations of olanzapine with mood stabilizers. Methods: This study was a randomized, double-blind, placebo-controlled, within-subject trial in adult psychiatric patients who were receiving olanzapine combined with lithium (Li) or valproate sodium (VPA). Omega-3 as fish oil with less than 1 g/day of EPA/DHA or its placebo was added to patients’ olanzapine and mood stabilizer regimens for 6 weeks. Metabolic parameters including anthropometric variables, lipid profile, metabolic syndrome indices, C-reactive protein, fibrinogen and lipoprotein (a) [(Lp) (a)] were assessed for participants. Results: Forty one participants completed this study; 20 patients received omega-3 and 21 patients received placebo, added to their regimen of SGA and mood stabilizer. Omega-3 addition did not modulate anthropometric, metabolic syndrome and lipid parameter changes in 6 weeks. However, fibrinogen levels significantly decreased, Lp (a) did not